Amylyx Pharmaceuticals (AMLX) is back in focus after announcing plans to present late breaking Phase 3 LUCIDITY data on avexitide for post bariatric hypoglycemia at ObesityWeek 2026.
Recent trading has been choppy for Amylyx Pharmaceuticals, with the share price down 19.65% over the past 30 days even after a 0.67% 1 day share price gain. However, momentum over a longer horizon looks stronger, with a 58.81% 90 day share price return and a 71.18% 1 year total shareholder return, reflecting how expectations around avexitide and the broader pipeline have shifted as data milestones approach.
Scan beyond Amylyx Pharmaceuticals and see how other rare disease and specialty treatment plays are setting up right now with our handpicked 20 high quality undiscovered gems
Amylyx Pharmaceuticals now carries a richer share price and fresh trial momentum. The real tension is simple: Does the current setup still leave more upside than downside for new buyers?
Most Popular Narrative: 36% Undervalued
At a last close of $27.03 against a narrative fair value of $42.36, Amylyx Pharmaceuticals screens as materially cheaper than that framework suggests. This puts the focus squarely on whether the projected ramp in avexitide and the broader pipeline can justify that gap under a 7.24% discount rate.
The company is targeting post bariatric hypoglycemia, a condition with no FDA approved therapies and an estimated 160,000 patients in the U.S., which creates room for a first approved product like avexitide to establish a new revenue line if pricing and access are secured.
See why 2 investors see Amylyx Pharmaceuticals as 36% undervalued.
Result: Fair Value of $42.36 (UNDERVALUED)
Still, the whole Amylyx Pharmaceuticals narrative hinges on LUCIDITY and avexitide execution. Disappointing data or slower than expected PBH uptake could quickly challenge today’s upside story.
Find out about the key risks to this Amylyx Pharmaceuticals narrative.
Next Steps
If the mixed sentiment around Amylyx Pharmaceuticals leaves you on the fence, move quickly through the data and weigh both sides for yourself with the 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Amylyx Pharmaceuticals?
If Amylyx Pharmaceuticals has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that line up with your risk, income and quality goals.
- Target potential mispricings by scanning companies that look attractively valued using the Simply Wall St screener for 32 high quality undervalued stocks.
- Strengthen the income side of your portfolio by checking out steady payers through the screener focused on 7 dividend fortresses.
- Dial down risk and focus on resilience by reviewing stocks filtered for quality and stability using the screener of 32 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com